Skip to main content
BioLineRx Ltd. logo

BioLineRx Ltd. — Investor Relations & Filings

Ticker · BLRX ISIN · US09071M2052 LEI · 529900AKIOSC15Y63R18 TA Manufacturing
Open in API
Filings indexed 1,676 across all filing types
Latest filing 2022-01-18 Regulatory Filings
Country IL Israel
Listing TA BLRX

About BioLineRx Ltd.

https://www.biolinerx.com/

BioLineRx Ltd. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for oncology and rare diseases. The company leverages its drug development capabilities to advance novel, early-stage therapeutic candidates through the clinical development process toward regulatory approval. Its pipeline consists of treatments, including small molecules, designed to address unmet medical needs and deliver meaningful benefits to patients. BioLineRx also partners with other drug developers to advance their early-stage programs.

Recent filings

Filing Released Lang Actions
6-K
Regulatory Filings
2022-01-18 English
BioLineRx Announces Successful Completion of Pre-NDA Meeting with FDA for Motixafortide for Stem Cell Mobilization in Multiple Myeloma Patient
Regulatory Filings Classification · 98% confidence The document is explicitly titled 'FORM 6-K' and is filed with the 'SECURITIES AND EXCHANGE COMMISSION'. Form 6-K is a report filed by foreign private issuers to report material information that is made public outside of the U.S. The content is a press release announcing the successful completion of a pre-NDA meeting with the FDA regarding a drug candidate (Motixafortide) and confirming the NDA submission timeline. This type of material event disclosure, filed on Form 6-K, is a general regulatory filing that does not fit neatly into the more specific categories like 10-K (Annual Report), ER (Earnings Release), or CT (Call Transcript). Therefore, the most appropriate classification is the general regulatory filing fallback category, RNS (Regulatory Filings).
2022-01-18 English
BioLineRx Announces Successful Completion of Pre-NDA Meeting with FDA for Motixafortide for Stem Cell Mobilization in Multiple Myeloma Patient
Report Publication Announcement Classification · 98% confidence The document is an 'Immediate Report' filed with the Israel Securities Authority and the Tel Aviv Stock Exchange, referencing a Form 6-K filing (which is typically used for material events by foreign private issuers on the SEC). The core content announces the 'Successful Completion of Pre-NDA Meeting with FDA' and explicitly states, 'Attached hereto is a report on *BioLineRx Announces Successful Completion of Pre-NDA Meeting with FDA...* *FORM_6-K_18-Jan-2022_isa.pdf*'. Since the document itself is short and serves primarily to announce the publication of an attached/linked report (the 6-K PDF), it fits the definition of a Report Publication Announcement (RPA). It is not the full financial report (10-K or IR) nor a general regulatory filing (RNS) if a more specific category applies, and RPA is the best fit for announcing the release of another document.
2022-01-18 English
BioLineRx Provides Highlights from Oral Presentation Delivered at the 63rd American Society of Hematology (ASH) Annual Meeting & Exposition
Regulatory Filings Classification · 95% confidence The document is explicitly titled 'FORM 6-K' and is filed with the 'SECURITIES AND EXCHANGE COMMISSION'. Form 6-K is a report of a foreign private issuer, typically used to report material information that the company is required to disclose to its home country's regulators or stock exchange, or that it makes public in its home country. The content is a press release providing highlights from a presentation at the American Society of Hematology (ASH) Annual Meeting, detailing clinical trial results (GENESIS Phase 3 trial) and providing an update on anticipated NDA submission timelines. This type of filing, which transmits material information disclosed outside the US, is generally classified under the broad 'Regulatory Filings' category when a more specific SEC form classification (like 10-K or DEF 14A) is not applicable. Since Form 6-K is a general reporting mechanism for foreign private issuers, and the content is a material update/press release, the most appropriate classification among the provided options is RNS (Regulatory Filings), which serves as the general regulatory announcement fallback.
2021-12-17 English
BioLineRx Provides Highlights from Oral Presentation Delivered at the 63rd American Society of Hematology (ASH) Annual Meeting & Exposition
Report Publication Announcement Classification · 98% confidence The document is an 'Immediate Report' filed with the Israel Securities Authority (ISA) and the Tel Aviv Stock Exchange, referencing a presentation given at the 63rd American Society of Hematology (ASH) Annual Meeting & Exposition. The text explicitly states: 'Attached hereto is a report on *BioLineRx Provides Highlights from Oral Presentation Delivered at the 63rd American Society of Hematology (ASH) Annual Meeting & Exposition*'. This structure—a brief announcement stating that presentation materials are attached or linked—fits the definition of a Report Publication Announcement (RPA) or potentially a general Regulatory Filing (RNS), based on the 'MENU VS MEAL' rule. Since the content describes the release of presentation highlights from a specific meeting, and the document itself is short and points to an attached PDF containing the actual content, RPA is the most precise fit, as it announces the publication of specific materials. If RPA were not available, RNS would be the fallback.
2021-12-17 English
6-K
Regulatory Filings
2021-12-17 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.